Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in ...
What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...
We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...
Zacks Investment Research on MSN3d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
But that's not all. From Eli Lilly's other recent launches, such as cancer medicine Jaypirca, to exciting pipeline candidates like Retatrutide -- a potential next-gen anti-obesity medicine -- not ...
Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca ...
Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback